Anbio Biotechnology (NASDAQ:NNNN) Shares Up 11.6% - Time to Buy?

Key Points

• Anbio Biotechnology shares jumped 11.6% Monday, trading as high as $31.57 and last at $32.2460 on light volume (10,026 shares, about 79% below the average session volume), up from a prior close of $28.90.
• Weiss Ratings downgraded the stock from a "hold (c-)" to a "sell (d+)" and the stock's average analyst rating on MarketBeat is currently "Sell."
• Anbio reported $0.03 earnings per share for the quarter and its 50-day moving average is $25.06.

Anbio Biotechnology (NASDAQ:NNNN - Get Free Report) traded up 11.6% during mid-day trading on Monday . The company traded as high as $31.57 and last traded at $32.2460. 10,026 shares changed hands during trading, a decline of 79% from the average session volume of 48,395 shares. The stock had previously closed at $28.90.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded Anbio Biotechnology from a "hold (c-)" rating to a "sell (d+)" rating in a report on Wednesday, April 1st. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of "Sell".

Anbio Biotechnology Price Performance

The company's fifty day moving average is $25.06.

Anbio Biotechnology (NASDAQ:NNNN - Get Free Report) last issued its earnings results on Tuesday, April 7th. The company reported $0.03 earnings per share for the quarter.

About Anbio Biotechnology

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.